Quadracel Purple Book BLA 125525

BLA number
125525
Proprietary names
Quadracel
Proper names
Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine
Applicant
Sanofi Vaccines Canada Ltd.
Center
CBER
First observed release
2020-08-01
Latest observed release
2026-06-01
Newest archive release
2026-06-01
FDA patent list
No patents listed in the captured FDA patent list; source updated 2025-06-11
Coverage
Present in newest release

Latest Known Product Presentations#

Product, Proprietary name, Proper name table
ProductProprietary nameProper nameLicense typeStrengthDosage formRoutePresentationMarketingLicensureApprovalPatent list provided
001QuadracelDiphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine351(a)0.5MLInjectionIntramuscularSingle-Dose VialDiscLicensed2015-03-24
002QuadracelDiphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine351(a)0.5MLInjectionIntramuscularPre-Filled SyringeRxLicensed2022-01-25

Published Patent List#

No patents for this BLA were listed in the FDA Purple Book patent list captured from the source updated 2025-06-11.

Official Monthly Change Events#

Release, Event, Product table
ReleaseEventProductNameLicense typeStatusApplicant
2026-05-01U001Quadracel351(a)DiscSanofi Vaccines Canada Ltd.
2026-05-01U002Quadracel351(a)RxSanofi Vaccines Canada Ltd.
2025-12-01U001Quadracel351(a)DiscSanofi Pasteur Limited
2025-12-01U002Quadracel351(a)RxSanofi Pasteur Limited
2021-05-01U001Quadracel351(a)RxSanofi Pasteur Limited
2020-08-01R001Quadracel351(a)RxSanofi Pasteur Limited

Observed Product State History#

Release, Product, Name table
ReleaseProductNameLicense typeMarketingLicensureApproval
2025-12-01001Quadracel351(a)DiscLicensed2015-03-24
2025-12-01002Quadracel351(a)RxLicensed2022-01-25
2020-08-01001Quadracel351(a)RxLicensed2015-03-24